Request Demo
Last update 24 May 2025
AMG-427 (Amgen)
Last update 24 May 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-FLT3 x anti-CD3 BiTE, emirodatamab, FLT3 HLE BITE + [5] |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 13030094
Source: *****
Related
1
Clinical Trials associated with AMG-427 (Amgen)NCT03541369
A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia.
100 Clinical Results associated with AMG-427 (Amgen)
Login to view more data
100 Translational Medicine associated with AMG-427 (Amgen)
Login to view more data
100 Patents (Medical) associated with AMG-427 (Amgen)
Login to view more data
100 Deals associated with AMG-427 (Amgen)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Phase 1 | China | 09 Dec 2020 | |
| Refractory acute myeloid leukemia | Phase 1 | United States | 14 Sep 2018 | |
| Refractory acute myeloid leukemia | Phase 1 | Japan | 14 Sep 2018 | |
| Refractory acute myeloid leukemia | Phase 1 | Australia | 14 Sep 2018 | |
| Refractory acute myeloid leukemia | Phase 1 | Canada | 14 Sep 2018 | |
| Refractory acute myeloid leukemia | Phase 1 | Germany | 14 Sep 2018 | |
| Relapsing acute myeloid leukemia | Phase 1 | United States | 14 Sep 2018 | |
| Relapsing acute myeloid leukemia | Phase 1 | Japan | 14 Sep 2018 | |
| Relapsing acute myeloid leukemia | Phase 1 | Australia | 14 Sep 2018 | |
| Relapsing acute myeloid leukemia | Phase 1 | Canada | 14 Sep 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free